Claudio Albrecht, CEO of Actavis drug maker, with 1.7bn-euroturnover in 2010, which owns Sindan plant in Romania, says a Swissor an Austrian would not have the same results as the Romanianteam, with Romanians having capacity for improvisation, beingintelligent and well-trained.
On the Romanian market, one of the most important in CEE,Actavis expects annual average growth of 15-20% in the followingyears because it started from a "very small" base.
Last year, Actavis posted 93m-euro sales (including exports) inRomania. In Albrecht's opinion, the local drug market also has"huge" potential.
The Sindan plant Actavis owns in Bucharest now works at fullcapacity and is one of the biggest pharmaceutical exporters.
"The more we grow, the more we have to move to Italy (whereActavis owns an cancer drug production facility," said Albrecht,adding he does not have any plans for a greenfield investment now,but that on long term it remains to be seen whether the plant keepsits current location (in the centre of Bucharest) or not.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
